Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & & Johnson
JNJ,
-0.19%.
stated Thursday that its lead vaccine candidate secured against infection with SARS-CoV-2, the virus that triggers COVID-19, in pre-clinical research studies. The vaccine … [+719 chars]